Congress finds the following: (1) The 2001 report of the Medicare Payment Advisory Commission to Congress states that to help ensure beneficiaries' access to highquality care, Medicare payments should correspond to the cost efficient providers incur in furnishing this care. During the third quarter of 2006, 44 percent of IVIG sales to hospitals and 41 percent of sales to physicians by the three largest distributors occurred at prices above Medicare payment amounts. Section 1842(o) of such Act (42 U.S.C. 1395u(o)), as amended by section 3(a), is amended (1) in paragraph (1)(E)(ii), by striking paragraph (7) and inserting paragraph (7) or (8); (2) by redesignating paragraph (8) as paragraph (9); and (3) by inserting after paragraph (7) the following new paragraph: (8)(A) Subject to subparagraph (B), in the case of intravenous immune globulins described in section 1861(s)(2)(Z) that are furnished on or after January 1, 2010, the Secretary shall provide for a separate payment for items and services related to the administration of such intravenous immune globulins in an amount that the Secretary determines to be appropriate based on a review of available published and unpublished data and information, including the Study of Intravenous Immune Globulin Administration Options: Safety, Access, and Cost Issues conducted by the Secretary (CMS Contract #500950059). 4. Coverage and payment of intravenous immune globulin in the home. Section 1861 of the Social Security Act (42 U.S.C. 1395x) is amended (1) in subsection (s)(2)(Z), by inserting and items and services related to the administration of intravenous immune globulin after globulin; and (2) in subsection (zz), by striking but not including items or services related to the administration of the derivative,. The amendments made by subsections (a) and (b) shall apply to intravenous immune globulin administered on or after January 1, 2010. SECTION 1.